Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about recommendations for Copper Tripeptide-1 solutions to enhance hair loss treatment, with a focus on using Reviv Hair Serum alongside LLLT therapy. The user also discusses using Minoxidil, RU58841, and other compounds to manage hair shedding and improve hair thickness.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

The conversation discusses combining topical cetirizine with minoxidil for hair loss treatment and inquires about the safety and absorption through the skin, as well as the possibility of adding melatonin.

Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.

The conversation discusses how applying topical tretinoin for 5 days can convert 43% of individuals who initially do not respond to minoxidil into responders, enhancing the effect of minoxidil on hair growth. Specific treatments mentioned are minoxidil and tretinoin.

Clascoterone is being discussed for hair loss, but its current acne formulation may not be suitable for scalp use due to potential skin irritation and lower dosage compared to Breezula. Users mention other treatments like finasteride, minoxidil, and pyrilutamide, with some expressing skepticism about clascoterone's effectiveness for hair loss.

The user has been using minoxidil for 5 years and finasteride for 7 months, with recent addition of tretinoin cream causing significant hair shedding. Other users suggest the shedding indicates effectiveness and recommend continuing tretinoin use.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

Hair loss treatments pyrilutamide and GT20029 discussed. Pyrilutamide approval in 2 years, GT20029 in 5-6+ years.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

The conversation discusses progress with a hair loss treatment regimen that includes once daily topical Finasteride, Pyrilutamide, and WAY-316606. Specific treatments for hair loss are being shared and discussed.

User discusses using C60 serum with microneedling at 1.75mm and asks if it's safe. Current routine includes daily Pyril on temples, weekly microneedling, and C60 serum on non-Pyril days.

A 35-year-old man underwent a hair transplant with Dr. Patty at HairTran Clinic in Bangkok, receiving 4,037 grafts primarily for his crown area. The procedure cost 188,700 THB, with an additional 12,000 THB for optional PRP treatment, and he plans to update with progress pictures in a year.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

An update on the use of Pyrilutamide, a new drug for hair loss, which has resulted in no shedding or testicle ache; other users have questioned the science behind this and shared their own experiences with Finasteride, Minoxidil, and microneedling.

Scientists discovered a new T cell treatment that could regrow hair. Users are skeptical but hopeful, with some relying on finasteride and minoxidil in the meantime.

Switching from ketoconazole to a ciclopirox and zinc pyrithione shampoo significantly reduced hair fall. The user is considering whether to continue using ketoconazole occasionally or combine both shampoos weekly.

The conversation discusses hair loss treatments including finasteride, minoxidil, derma rolling, and tretinoin, with the user showing progress after five months. Tretinoin is mentioned to enhance the effectiveness of minoxidil.

The user is considering using tretinoin with topical finasteride due to poor absorption and side effects from oral finasteride. They are also contemplating switching to topical dutasteride, while others suggest trying oral minoxidil or lower oral doses.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

The user is considering switching to oral dutasteride, topical minoxidil, retinoic acid, and clobetasol for hair loss treatment, after limited regrowth with finasteride and other topicals. They are seeking a source for clobetasol, as they believe it may help with their condition.

A male in his early 20s with CCCA (scarring alopecia) started treatment with Finasteride, Fluocinolone, and Doxycycline. Steroid injections were suggested but not yet done.

The user experienced significant hair regrowth using Trestolone, GHK-Cu, and Minoxidil. They avoided Finasteride due to concerns about side effects and noted that their approach reduced androgenic load, contributing to hair regrowth.

The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.

A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

The conversation discusses a transgender individual's successful hair loss treatment over 1.5 years using 2.5mg oral minoxidil, 5mg finasteride, and 8mg weekly injectable estradiol valerate. Some users debate the appropriateness of this approach within the group's goals, while others support the individualized treatment and its additional benefits for transgender individuals.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.